ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, the first line of treatment for CML, inhibits BCR-ABL (breakpoint cluster region-Abelson) tyrosine kinase activity by blocking the ATP-binding site [2].